# PROVISIONAL PATENT APPLICATION

## United States Patent and Trademark Office

**Application Type:** Provisional Application under 35 U.S.C. § 111(b)

---

# System and Method for Adaptive Acoustic Neuromodulation via State-Space Biomarker Gating

---

## INVENTOR(S)

**Carl Zimmerman**
Charlotte, North Carolina, United States

---

## CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the filing date and is a provisional application.

---

## FIELD OF THE INVENTION

The present invention relates generally to medical devices and methods for treating neurodegenerative diseases, and more particularly to a cyber-physical system integrating computational biomarker analysis with patient-specific acoustic delivery devices for the treatment of protein aggregation disorders including Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS).

---

## BACKGROUND OF THE INVENTION

### The Failure of Chemical Interventions in Foldopathies

Neurodegenerative diseases, collectively termed "foldopathies" due to their common etiology of protein misfolding and aggregation, represent one of the greatest unmet medical needs of the 21st century. Despite decades of research and billions of dollars in investment, no disease-modifying treatment has successfully halted or reversed neurodegeneration.

**Alzheimer's Disease (AD):** Characterized by extracellular amyloid-beta (Aβ) plaques and intracellular tau tangles. Recent antibody therapies (aducanumab, lecanemab) have demonstrated amyloid clearance but failed to produce meaningful clinical improvement. The fundamental thermodynamic barrier—the free energy required to disaggregate stable cross-β sheet structures—exceeds what passive chemical chaperones can provide.

**Parkinson's Disease (PD):** Characterized by α-synuclein aggregates (Lewy bodies) spreading trans-synaptically through connected brain regions. No treatment halts this network propagation. Current therapies address symptoms (dopamine replacement) rather than the underlying spread mechanism.

**Amyotrophic Lateral Sclerosis (ALS):** Characterized by TDP-43 cytoplasmic aggregation, axonal transport failure, excitotoxicity, and neuromuscular junction degeneration. The only approved treatments (riluzole, edaravone) provide minimal survival extension (2-3 months) because they fail to address the multi-modal nature of the pathology.

### Limitations of Current Acoustic Interventions

Focused ultrasound (FUS) has emerged as a promising modality for neurological treatment, with FDA-approved applications for essential tremor ablation and ongoing trials for blood-brain barrier (BBB) opening. However, current implementations suffer from critical limitations:

1. **Un-gated Delivery:** Existing FUS protocols deliver acoustic energy without regard to the patient's inflammatory or metabolic state. Computational modeling and early clinical data suggest that BBB opening and subsequent therapeutic delivery during active neuroinflammation may cause iatrogenic harm, including accelerated neuronal death.

2. **Static Treatment Protocols:** Current approaches use fixed acoustic parameters without adaptation to patient-specific skull geometry, disease state, or real-time biomarker feedback.

3. **Expensive Hardware:** Clinical FUS systems employ active phased arrays costing $1-10 million, limiting deployment to major academic centers and excluding the majority of patients who could benefit.

4. **Monotherapy Focus:** Existing approaches test single interventions (antibodies alone, ultrasound alone) rather than recognizing that multi-modal, sequenced interventions are mathematically required for disease reversal.

### The Need for Biomarker-Gated, Adaptive Acoustic Neuromodulation

The present invention addresses these limitations through a novel cyber-physical system that integrates:

1. Computational state-space modeling of disease progression
2. Real-time biomarker gating derived from Markov Decision Process optimization
3. Patient-specific passive acoustic focusing via 3D-printed metamaterial lenses
4. Adaptive clinical trial methodology enabling sequence optimization

---

## SUMMARY OF THE INVENTION

The present invention provides a system and method for treating neurodegenerative diseases through adaptive acoustic neuromodulation controlled by state-space biomarker gating.

In one embodiment, the invention comprises:

**A. A Computational Biomarker Gating System** that evaluates patient state based on a composite "Inflammation Index" derived from multiple biomarker inputs, and controls progression through treatment phases based on mathematically-derived thresholds.

**B. A Patient-Specific Acoustic Focusing Device** comprising a single-element ultrasound transducer coupled to a 3D-printed passive metamaterial lens that corrects for patient-specific skull aberrations, achieving precise focal targeting at a fraction of the cost of active phased arrays.

**C. A Manufacturing Pipeline** that converts patient CT scan data to acoustic property maps, computes holographic phase corrections via ray-tracing and wave simulation, and generates 3D-printable lens geometries.

**D. A Bayesian Adaptive Trial Engine** that dynamically optimizes treatment sequences across patient populations using response-adaptive randomization informed by the biomarker gating system.

The cyber-physical loop operates as follows: The AI engine evaluates the patient's Inflammation Index. If the Index exceeds a threshold (e.g., 0.3), regenerative treatments are blocked and the patient is routed to anti-inflammatory protocols. Only when the Index drops below threshold does the system unlock acoustic BBB opening and subsequent therapeutic phases. This gating prevents the catastrophic outcome of regenerative therapy in an inflamed neural environment—a failure mode mathematically demonstrated through Markov Decision Process simulation.

---

## BRIEF DESCRIPTION OF THE DRAWINGS

[Note: In the actual filing, figures would be included. Descriptions provided here for reference.]

**FIG. 1** is a block diagram of the complete cyber-physical system showing the biomarker sensing subsystem, computational gating engine, acoustic delivery subsystem, and feedback loops.

**FIG. 2** is a flowchart of the six-phase treatment algorithm with biomarker gates.

**FIG. 3** is a cross-sectional diagram of the acoustic delivery assembly showing the transducer, metamaterial lens, coupling medium, and patient skull interface.

**FIG. 4** is an illustration of the labyrinthine unit cell structure of the metamaterial lens.

**FIG. 5** is a diagram of the CT-to-lens computational pipeline.

**FIG. 6** is a graph showing the Inflammation Index threshold and its effect on treatment outcomes derived from MDP simulation.

**FIG. 7** is a state-transition diagram of the Markov Decision Process model underlying the gating logic.

**FIG. 8** is a plot of acoustic pressure distribution showing focal confinement achieved by the metamaterial lens.

---

## DETAILED DESCRIPTION OF THE INVENTION

### 1. System Overview

The present invention comprises an integrated system for adaptive acoustic neuromodulation. The system includes:

1.1 **Biomarker Sensing Subsystem:** Interfaces with clinical laboratory systems to receive biomarker measurements including but not limited to:
   - High-sensitivity C-reactive protein (hs-CRP)
   - Cerebrospinal fluid (CSF) interleukin-6 (IL-6)
   - CSF tumor necrosis factor alpha (TNF-α)
   - TSPO-PET imaging signal (microglial activation)
   - Soluble TREM2 (sTREM2)
   - Neurofilament light chain (NfL)
   - Disease-specific markers (Aβ42/40, α-synuclein, TDP-43)

1.2 **Computational Gating Engine:** Processes biomarker inputs to compute composite indices and evaluate gate conditions. Implemented as software running on standard computing hardware or cloud infrastructure.

1.3 **Acoustic Delivery Subsystem:** Comprises:
   - Single-element ultrasound transducer (e.g., 1.5 MHz center frequency)
   - Patient-specific 3D-printed metamaterial acoustic lens
   - Acoustic coupling medium (degassed water)
   - Positioning system (stereotactic frame or robotic arm)
   - Real-time monitoring sensors (passive cavitation detector, temperature sensors)

1.4 **Manufacturing Subsystem:** Comprises:
   - CT scan acquisition interface
   - Phase map computation software
   - 3D printer (stereolithography or equivalent)
   - Quality control and calibration equipment

1.5 **Adaptive Trial Engine:** Bayesian software system for multi-arm clinical trials with response-adaptive randomization.

### 2. The Six-Phase Treatment Algorithm

The treatment protocol proceeds through six phases, with biomarker gates controlling transitions:

**Phase 1: Gut/BBB Preparation (Weeks 0-4)**
- Microbiome optimization to reduce lipopolysaccharide (LPS) translocation
- Tight junction enhancement via zonulin modulators
- Baseline biomarker collection
- No acoustic intervention in this phase

**Phase 2: Anti-Inflammation (Weeks 4-12)**
- Microglial modulation (e.g., CSF1R inhibitors)
- Systemic inflammation reduction
- Continuous biomarker monitoring
- **GATE CONDITION:** Inflammation Index must fall below 0.3 to proceed

**Phase 3: BBB Opening (Week 12+, gated)**
- Low-Intensity Focused Ultrasound (LIFU) delivery via patient-specific lens
- Acoustic parameters: 0.2-0.6 MPa in situ, 1.5 MHz, 1% duty cycle
- Microbubble contrast agent administration
- Creates 4-6 hour therapeutic delivery window

**Phase 4: Mechanical Clearance (Concurrent with Phase 3)**
- Monoclonal antibody infusion during BBB-open window
- Optional: Mathieu resonance acoustic stimulation for fibril disaggregation
- **GATE CONDITION:** Clearance Index must exceed 0.5 to proceed

**Phase 5: Synaptic Regeneration (Week 16+, doubly-gated)**
- Neurotrophic factor delivery (BDNF, GDNF)
- Synaptogenic compounds
- Activity-dependent plasticity protocols
- **CRITICAL:** This phase is BLOCKED if Inflammation Index > 0.3

**Phase 6: Maintenance (Ongoing)**
- Periodic BBB opening for sustained clearance
- Inflammation monitoring with re-gating if needed
- Functional rehabilitation

### 3. The Inflammation Index and Gating Logic

The Inflammation Index (I) is computed as a weighted sum of normalized biomarkers:

```
I = w₁×norm(hs-CRP) + w₂×norm(IL-6) + w₃×norm(TNF-α) + w₄×norm(TSPO) + w₅×norm(sTREM2)
```

Where:
- norm(x) = (x - x_healthy) / (x_pathological - x_healthy), clipped to [0, 1]
- w₁ = 0.15, w₂ = 0.25, w₃ = 0.20, w₄ = 0.25, w₅ = 0.15

The threshold I ≤ 0.3 is derived from Markov Decision Process (MDP) simulation showing that regenerative therapy initiated when I > 0.3 results in catastrophic neuronal loss (MDP reward: -207) compared to proper sequencing (MDP reward: +366).

The gating logic is implemented as a state machine:

```
IF current_phase == PHASE_5_REGENERATION:
    IF inflammation_index > 0.3:
        BLOCK_PHASE_5()
        RETURN_TO_PHASE_2()
    ELSE:
        PROCEED_WITH_REGENERATION()
```

### 4. Patient-Specific Metamaterial Acoustic Lens

A key innovation of the present invention is the use of passive, 3D-printed metamaterial lenses to achieve patient-specific transcranial focusing without expensive active phased arrays.

**4.1 Acoustic Property Derivation from CT**

Patient CT scan data (Hounsfield Units) is converted to acoustic properties using empirically-validated relationships:

- Sound speed: c(HU) = 1540 + 0.93 × (HU - 300) m/s for HU > 300
- Density: ρ(HU) = 1000 + 0.523 × HU kg/m³ for HU > 300
- Attenuation: α(HU) = 0.5 + 0.022 × (HU - 300) dB/cm/MHz for HU > 300

**4.2 Phase Map Computation**

For each element position on the transducer surface, the required phase correction is computed by:

1. Ray-tracing from element to target through the skull
2. Integrating acoustic path length: τ = ∫ ds/c(x,y,z)
3. Computing phase: φ = 2πf × τ
4. Determining correction: Δφ = φ_reference - φ_actual

Full-wave simulation (e.g., k-space methods) refines the ray-tracing estimate.

**4.3 Metamaterial Lens Structure**

The lens comprises an array of labyrinthine unit cells, each providing a specific phase delay determined by the path length through the maze-like structure. A library of 16 unit cells covers phase delays from 0 to 2π in π/8 increments.

The lens is fabricated via stereolithography (SLA) 3D printing in rigid photopolymer resin with:
- Sound speed: ~2400 m/s
- Layer resolution: 50 μm
- Total thickness: 5-15 mm

**4.4 Focal Pressure Achievement**

The lens achieves constructive interference at the target, producing focal pressure:

```
P_focal = P_0 × G_focal × T_avg
```

Where:
- P_0 = transducer surface pressure
- G_focal = focusing gain (~10-20×)
- T_avg = average skull transmission (~0.5)

Design ensures P_focal = 0.2-0.6 MPa at target while P_skull < 0.1 MPa in beam path.

### 5. Rayleigh-Plesset Safety Constraints

The acoustic parameters are constrained by microbubble dynamics governed by the Rayleigh-Plesset equation:

```
ρ_L(R R̈ + 3/2 Ṙ²) = P_internal - P_0 - P_acoustic(t) - 4μṘ/R - 2σ/R
```

Safe BBB opening requires stable cavitation (R_max/R_0 < 5), achieved at:
- Pressure: 0.2-0.6 MPa (in situ, derated)
- Mechanical Index: MI < 0.8
- Frequency: 1-2 MHz

Inertial cavitation (hemorrhage risk) occurs above 0.8 MPa and is avoided through real-time cavitation monitoring and automatic shutoff.

### 6. Bayesian Adaptive Trial Engine

The invention includes a Bayesian adaptive trial engine implementing:

**6.1 Hierarchical Model:**
```
μ ~ Beta(2, 2)                         # Population mean
κ ~ Gamma(2, 0.5)                      # Concentration
θ_k ~ Beta(μκ, (1-μ)κ)                 # Arm-specific success rates
y_k ~ Binomial(n_k, θ_k)               # Observed outcomes
```

**6.2 Response-Adaptive Randomization:**
```
r_k(t) = [P(θ_k = max | data)]^γ / Σ_j [P(θ_j = max | data)]^γ
```

Where γ = 0.5 (square-root rule) balances exploration and exploitation.

**6.3 Stopping Rules:**
- Futility: P(θ_k > θ_control) < 0.10 → drop arm
- Superiority: P(θ_k > θ_control) > 0.99 → graduate arm

This engine enables the trial to automatically identify optimal treatment sequences while protecting patients from inferior approaches.

---

## CLAIMS

### Independent Claims

**Claim 1.** A method for treating a neurodegenerative disease in a patient, the method comprising:
   (a) measuring one or more biomarkers from the patient to determine an inflammation state;
   (b) computing an Inflammation Index from the measured biomarkers;
   (c) comparing the Inflammation Index to a predetermined threshold;
   (d) if the Inflammation Index exceeds the threshold, administering an anti-inflammatory intervention and repeating steps (a)-(c);
   (e) if the Inflammation Index is at or below the threshold, proceeding to acoustic neuromodulation comprising:
       (i) positioning a patient-specific acoustic focusing device adjacent to the patient's skull;
       (ii) delivering focused ultrasound energy to a target region in the patient's brain;
   (f) administering a therapeutic agent during a blood-brain barrier permeability window created by the focused ultrasound.

**Claim 2.** A system for adaptive acoustic neuromodulation, the system comprising:
   (a) a biomarker processing module configured to receive biomarker measurements and compute a composite index representing a patient's inflammatory state;
   (b) a gating module configured to compare the composite index to a threshold and generate a gate signal indicating whether acoustic treatment is permitted;
   (c) an acoustic delivery device comprising:
       (i) an ultrasound transducer;
       (ii) a patient-specific passive acoustic lens configured to focus ultrasound energy through the patient's skull to a predetermined target;
   (d) a controller configured to enable the acoustic delivery device only when the gate signal indicates treatment is permitted.

**Claim 3.** A method for manufacturing a patient-specific acoustic focusing device, the method comprising:
   (a) acquiring computed tomography (CT) scan data of a patient's skull;
   (b) converting the CT data to acoustic property maps including sound speed, density, and attenuation;
   (c) computing a phase correction map by simulating acoustic propagation from a transducer surface through the skull to a target location;
   (d) converting the phase correction map to a physical lens geometry;
   (e) fabricating the lens geometry using additive manufacturing.

### Dependent Claims

**Claim 4.** The method of Claim 1, wherein the biomarkers comprise at least two of: high-sensitivity C-reactive protein, cerebrospinal fluid interleukin-6, cerebrospinal fluid tumor necrosis factor alpha, TSPO-PET signal, and soluble TREM2.

**Claim 5.** The method of Claim 1, wherein the predetermined threshold for the Inflammation Index is 0.3 on a normalized scale of 0 to 1.

**Claim 6.** The method of Claim 1, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis.

**Claim 7.** The system of Claim 2, wherein the patient-specific passive acoustic lens comprises a metamaterial structure with labyrinthine unit cells providing spatially-varying phase delays.

**Claim 8.** The system of Claim 2, wherein the acoustic delivery device is configured to deliver focused ultrasound at a pressure between 0.2 and 0.6 MPa at the target location while maintaining pressure below 0.1 MPa in intervening tissue.

**Claim 9.** The method of Claim 3, wherein computing the phase correction map comprises:
   (a) ray-tracing from each transducer element position to the target location through the acoustic property maps;
   (b) integrating acoustic travel time along each ray path;
   (c) computing phase corrections to achieve constructive interference at the target.

**Claim 10.** The method of Claim 3, wherein the additive manufacturing comprises stereolithography using a photopolymer resin with acoustic sound speed between 2000 and 3000 m/s.

**Claim 11.** A method for conducting an adaptive clinical trial of neurodegenerative disease treatments, the method comprising:
   (a) enrolling patients into one of a plurality of treatment sequence arms;
   (b) measuring treatment outcomes including biomarker-based gate passage and primary endpoints;
   (c) updating posterior probability distributions for each arm using Bayesian inference;
   (d) computing updated randomization weights based on the posterior probabilities;
   (e) applying response-adaptive randomization to assign subsequent patients preferentially to arms with higher posterior probabilities of success;
   (f) evaluating stopping rules for futility and superiority.

**Claim 12.** The method of Claim 11, wherein the Bayesian inference comprises Markov Chain Monte Carlo sampling from a hierarchical model.

---

## ABSTRACT

A system and method for treating neurodegenerative diseases through adaptive acoustic neuromodulation controlled by state-space biomarker gating. The system comprises a computational engine that evaluates a patient's Inflammation Index from multiple biomarker inputs and controls progression through a multi-phase treatment algorithm. A patient-specific passive acoustic lens, manufactured via 3D printing based on CT-derived phase maps, focuses ultrasound through the skull to deep brain targets for blood-brain barrier opening and therapeutic delivery. The gating system prevents regenerative therapies from proceeding when inflammation exceeds a threshold derived from Markov Decision Process optimization, thereby avoiding iatrogenic harm. A Bayesian adaptive trial engine enables response-adaptive randomization to optimize treatment sequences across patient populations. The invention addresses the failures of prior chemical interventions and un-gated acoustic therapies by integrating computational state-space modeling with patient-specific acoustic delivery in a closed-loop cyber-physical system.

---

## FILING INFORMATION

**Filing Type:** Provisional Application under 35 U.S.C. § 111(b)

**Entity Status:** Micro Entity (if applicable)

**Filing Fee:** As per current USPTO fee schedule

**Duration:** 12 months from filing date to file non-provisional application

---

*This document is a draft for provisional patent filing purposes. Formal filing requires completion of USPTO forms (SB/16, cover sheet) and payment of applicable fees.*
